BR112023023726A2 - Compostos heterocíclicos substituídos - Google Patents

Compostos heterocíclicos substituídos

Info

Publication number
BR112023023726A2
BR112023023726A2 BR112023023726A BR112023023726A BR112023023726A2 BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2 BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2
Authority
BR
Brazil
Prior art keywords
substituted heterocyclic
heterocyclic compounds
compounds
useful
tyk
Prior art date
Application number
BR112023023726A
Other languages
English (en)
Inventor
Edward Mertzman Michael
M Moslin Ryan
H Spergel Steven
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112023023726A2 publication Critical patent/BR112023023726A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos heterocíclicos substituídos. a presente invenção refere-se a compostos da seguinte fórmula i: ou um estereoisômero ou sal farmaceuticamente aceitável do mesmo, em que todos os substituintes são conforme definidos no presente documento, os quais são úteis na modulação de il-12, il-23 e/ou ifna, ao agir na tyk-2 para causar a inibição de transdução de sinal. os compostos da invenção podem ser úteis para o tratamento de doenças ou transtornos neurodegenerativos.
BR112023023726A 2021-05-14 2022-05-13 Compostos heterocíclicos substituídos BR112023023726A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US202263318508P 2022-03-10 2022-03-10
PCT/US2022/029117 WO2022241174A1 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR112023023726A2 true BR112023023726A2 (pt) 2024-01-30

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023726A BR112023023726A2 (pt) 2021-05-14 2022-05-13 Compostos heterocíclicos substituídos

Country Status (11)

Country Link
US (2) US11884650B2 (pt)
EP (1) EP4337648A1 (pt)
JP (1) JP2024518555A (pt)
KR (1) KR20240008338A (pt)
AU (1) AU2022272725A1 (pt)
BR (1) BR112023023726A2 (pt)
CA (1) CA3218579A1 (pt)
IL (1) IL308422A (pt)
MX (1) MX2023013351A (pt)
TW (1) TW202311248A (pt)
WO (1) WO2022241174A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117200A1 (en) 2018-10-22 2020-04-30 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
AU2019373203A1 (en) * 2018-10-30 2021-06-10 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

Also Published As

Publication number Publication date
CA3218579A1 (en) 2022-11-17
JP2024518555A (ja) 2024-05-01
US11884650B2 (en) 2024-01-30
AU2022272725A1 (en) 2024-01-04
MX2023013351A (es) 2023-11-27
US20220388987A1 (en) 2022-12-08
US20240124421A1 (en) 2024-04-18
TW202311248A (zh) 2023-03-16
EP4337648A1 (en) 2024-03-20
WO2022241174A1 (en) 2022-11-17
KR20240008338A (ko) 2024-01-18
IL308422A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112023023425A2 (pt) Compostos heterocíclicos substituídos
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
BR112015022575A2 (pt) composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
EA202090068A1 (ru) Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний
BR112022020291A2 (pt) Inibidores de cd38
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
MX2022003490A (es) Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6).
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
BR112021019817A2 (pt) Compostos de pirrol
BR112022024156A2 (pt) Compostos heterocílicos antelmínticos
BR112023012947A2 (pt) Inibidores de lrrk2
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112019023130A2 (pt) Compostos e métodos para tratamento de infecções bacterianas
BR112023023726A2 (pt) Compostos heterocíclicos substituídos